GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of is it normal to get muscle cramps at week 88 — 32 comments in the full submission. View in context.
2.7k
c/survodutide·submitted 1 year ago by u/kaia_wojcik

is it normal to get muscle cramps at week 88

Trial Databranch of 7 comments

Check-in as promised in the title: is it normal to get muscle cramps at week 88. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use. Independent purity results for this compound are very sparse across the whole site, which means any impression about…

Read the full submission and all 32 comments →

This branch

7 comments, started 1 year ago
u/patient_labslip_log261 points·1 year ago

the titration in the trials was slow and deliberate

replysharereportpermalink
u/sofia_ferreira-38 points·1 year ago

Disagree — that is a weight endpoint from a different programme and you are quoting it in a hepatic context.

replysharereportpermalink
u/milan_mensah1 point·1 year ago

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

replysharereportpermalink
u/kaia_wojcikOP1 point·1 year ago

Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.

replysharereportpermalink
u/kaia_wojcikOP0 points·1 year ago

Which endpoint — histological response, fibrosis improvement, or fat fraction?

replysharereportpermalink
u/honest_syringe_pls1 point·1 year ago

Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.

replysharereportpermalink
u/paper_trail_paulavetting1 point·1 year ago

That figure is from the obesity programme, and this thread is about the hepatic one.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →